NASDAQ:DOCS Doximity (DOCS) Stock Price, News & Analysis → Things Are Not Normal in America – Here’s What to Do (From Stansberry Research) (Ad) Free DOCS Stock Alerts $23.76 -0.12 (-0.50%) (As of 04:10 PM ET) Add Compare Share Share Today's Range$23.60▼$24.1650-Day Range$23.59▼$28.6852-Week Range$19.71▼$36.29Volume1.20 million shsAverage Volume1.67 million shsMarket Capitalization$4.43 billionP/E Ratio36.00Dividend YieldN/APrice Target$28.82 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Doximity alerts: Email Address Doximity MarketRank™ Stock AnalysisAnalyst RatingHold2.07 Rating ScoreUpside/Downside21.7% Upside$28.82 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 13 Articles This WeekInsider TradingSelling Shares$67,425 Sold Last QuarterProj. Earnings Growth6.94%From $0.72 to $0.77 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.44 out of 5 starsMedical Sector290th out of 915 stocksCustom Computer Programming Services Industry11th out of 24 stocks 3.0 Analyst's Opinion Consensus RatingDoximity has received a consensus rating of Hold. The company's average rating score is 2.07, and is based on 2 buy ratings, 11 hold ratings, and 1 sell rating.Amount of Analyst CoverageDoximity has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Doximity's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DOCS. Previous Next 0.0 Dividend Strength Dividend YieldDoximity does not currently pay a dividend.Dividend GrowthDoximity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DOCS. Previous Next 3.0 News and Social Media Coverage News SentimentDoximity has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Doximity this week, compared to 5 articles on an average week.Search Interest9 people have searched for DOCS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows11 people have added Doximity to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Doximity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $67,425.00 in company stock.Percentage Held by Insiders39.40% of the stock of Doximity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.19% of the stock of Doximity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Doximity's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Doximity are expected to grow by 6.94% in the coming year, from $0.72 to $0.77 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Doximity is 35.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.61.Price to Earnings Ratio vs. SectorThe P/E ratio of Doximity is 35.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 170.94.Price to Earnings Growth RatioDoximity has a PEG Ratio of 3.03. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDoximity has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Doximity's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThings Are Not Normal in America – Here’s What to DoGet Out of the Dollar Before May 15 A Wall Street legend and our friend has just warned 896,000 Americans to prepare for May 15.This could be your solution. About Doximity Stock (NASDAQ:DOCS)Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.Read More DOCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DOCS Stock News HeadlinesMay 9, 2024 | prnewswire.comDOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud LawsuitMay 9, 2024 | americanbankingnews.comDoximity (DOCS) Scheduled to Post Quarterly Earnings on ThursdayMay 9, 2024 | InvestorPlace (Ad)1970’s computer coder Issues Shocking AI WarningLouis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.May 8, 2024 | prnewswire.comROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCSMay 8, 2024 | prnewswire.comDoximity, Inc. (DOCS) Investors: June 17, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPMay 7, 2024 | prnewswire.comDOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud LawsuitMay 6, 2024 | markets.businessinsider.comIMPORTANT DEADLINE ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the FirmMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. - DOCSMay 9, 2024 | InvestorPlace (Ad)1970’s computer coder Issues Shocking AI WarningLouis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.May 5, 2024 | stockhouse.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCSMay 5, 2024 | stockhouse.comDOCS SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Doximity, Inc. Investors Can Join the Class Action Lawsuit!May 3, 2024 | prnewswire.comDOXIMITY SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCSMay 3, 2024 | markets.businessinsider.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the FirmMay 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DoximityMay 2, 2024 | prnewswire.comDOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud LawsuitMay 2, 2024 | markets.businessinsider.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DoximityMay 1, 2024 | prnewswire.comDoximity, Inc. (DOCS) Investors: June 17, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPMay 1, 2024 | prnewswire.comIMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the FirmApril 30, 2024 | businesswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Doximity, Inc. (DOCS)April 30, 2024 | businesswire.comDOCS Investors With Large Losses Should Contact Robbins LLP for Information About Their Rights in Connection With the Doximity, Inc. Class Action LawsuitApril 29, 2024 | businesswire.comDeadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Doximity, Inc. (DOCS)April 29, 2024 | prnewswire.comClass Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Northern District of California against Doximity, Inc.April 29, 2024 | markets.businessinsider.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCSApril 28, 2024 | seekingalpha.comDoximity: Significant Upside Remains, But Not Until The Growth Story ReturnsApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. - DOCSApril 27, 2024 | prnewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCSApril 27, 2024 | markets.businessinsider.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DoximitySee More Headlines Receive DOCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Doximity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today5/09/2024Next Earnings (Confirmed)5/16/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Custom computer programming services Sub-IndustryN/A Current SymbolNASDAQ:DOCS CUSIPN/A CIK1516513 Webwww.doximity.com Phone650-549-4330FaxN/AEmployees977Year FoundedN/APrice Target and Rating Average Stock Price Target$28.82 High Stock Price Target$33.00 Low Stock Price Target$23.00 Potential Upside/Downside+20.6%Consensus RatingHold Rating Score (0-4)2.07 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$0.66 Trailing P/E Ratio36.20 Forward P/E Ratio33.18 P/E Growth3.03Net Income$112.82 million Net Margins29.39% Pretax Margin37.15% Return on Equity16.08% Return on Assets13.76% Debt Debt-to-Equity RatioN/A Current Ratio8.03 Quick Ratio8.03 Sales & Book Value Annual Sales$419.05 million Price / Sales10.64 Cash Flow$0.71 per share Price / Cash Flow33.53 Book Value$4.98 per share Price / Book4.80Miscellaneous Outstanding Shares186,550,000Free Float113,052,000Market Cap$4.46 billion OptionableNot Optionable Beta1.18 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Jeffrey A. Tangney (Age 51)Co-Founder, CEO & Chairperson Comp: $243.73kDr. Nate Gross M.D. (Age 40)Co-Founder & Chief Strategy Officer Comp: $455.54kMs. Anna Bryson (Age 34)Chief Financial Officer Comp: $453.71kMs. Jennifer W. Chaloemtiarana (Age 56)General Counsel & Corporate Secretary Comp: $504.04kMr. Paul Jorgensen (Age 53)Chief Revenue Officer Comp: $455.13kMs. Shari BuckCo-founder and SVP People & OpsMr. Jey BalachandranChief Technology OfficerMr. Perry Scott GoldHead of Investor RelationsJim RivasHead of Corporate CommunicationsMr. Bruno MirandaSenior VP of EngineeringMore ExecutivesKey CompetitorsKrystal BiotechNASDAQ:KRYSMadrigal PharmaceuticalsNASDAQ:MDGLMerit Medical SystemsNASDAQ:MMSINuvalentNASDAQ:NUVLCRISPR TherapeuticsNASDAQ:CRSPView All CompetitorsInsiders & InstitutionsBlair William & Co. ILBought 21,787 shares on 5/9/2024Ownership: 0.049%State Board of Administration of Florida Retirement SystemSold 1,462 shares on 5/9/2024Ownership: 0.047%Edmond DE Rothschild Holding S.A.Sold 326,550 shares on 5/8/2024Ownership: 1.059%Russell Investments Group Ltd.Bought 91,240 shares on 5/8/2024Ownership: 0.094%Qsemble Capital Management LPBought 30,861 shares on 5/8/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions DOCS Stock Analysis - Frequently Asked Questions Should I buy or sell Doximity stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Doximity in the last twelve months. There are currently 1 sell rating, 11 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" DOCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DOCS, but not buy additional shares or sell existing shares. View DOCS analyst ratings or view top-rated stocks. What is Doximity's stock price target for 2024? 14 analysts have issued 1-year target prices for Doximity's stock. Their DOCS share price targets range from $23.00 to $33.00. On average, they predict the company's share price to reach $28.82 in the next twelve months. This suggests a possible upside of 21.7% from the stock's current price. View analysts price targets for DOCS or view top-rated stocks among Wall Street analysts. How have DOCS shares performed in 2024? Doximity's stock was trading at $28.04 at the beginning of 2024. Since then, DOCS shares have decreased by 15.6% and is now trading at $23.67. View the best growth stocks for 2024 here. When is Doximity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024. View our DOCS earnings forecast. How can I listen to Doximity's earnings call? Doximity will be holding an earnings conference call on Thursday, May 16th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Doximity's earnings last quarter? Doximity, Inc. (NASDAQ:DOCS) issued its quarterly earnings results on Tuesday, November, 9th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.06 by $0.13. The company earned $79.35 million during the quarter, compared to analyst estimates of $73.60 million. Doximity had a trailing twelve-month return on equity of 16.08% and a net margin of 29.39%. What ETFs hold Doximity's stock? ETFs with the largest weight of Doximity (NASDAQ:DOCS) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Jacob Forward ETF (JFWD), Janus Henderson Small Cap Growth Alpha ETF (JSML), Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Renaissance IPO ETF (IPO), Pacer US Large Cap Cash Cows Growth Leaders ETF (COWG) and Natixis U.S. Equity Opportunities ETF (EQOP). When did Doximity IPO? Doximity (DOCS) raised $501 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 23,300,000 shares at $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan Securities served as the underwriters for the IPO and Piper Sandler, William Blair, Canaccord and Raymond James were co-managers. Who are Doximity's major shareholders? Doximity's stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.33%), William Blair Investment Management LLC (2.96%), Edmond DE Rothschild Holding S.A. (1.06%), Rice Hall James & Associates LLC (0.42%), Principal Financial Group Inc. (0.25%) and Swiss National Bank (0.12%). Insiders that own company stock include Anna Bryson, Craig Overpeck, Gilbert H Kliman, Interwest Partners X Lp, Joseph B Kleine, Kevin Spain, Kira Scherer Wampler, Paul W Jorgensen and Timothy S Cabral. View institutional ownership trends. How do I buy shares of Doximity? Shares of DOCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DOCS) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Doximity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
